Zentalis Pharmaceuticals’ $200.2 Million Common Stock Offering

Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here